Incyte reported on Thursday fourth quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Incyte announced earnings per share of $0.65 on revenue of $579.4M. Analysts polled by anticipated EPS of $0.35 on revenue of $576.62M. That with comparison to EPS of $0.32 on revenue of $528.4M in the same period a year before. Incyte had reported EPS of $0.59 on revenue of $551.58M in the previous quarter. Analysts are expecting EPS of $0.31 and revenue of $550.49M in the upcoming quarter.
Incyte shares are down 13.16% from the beginning of the year , still down 21.66% from its 52 week high of $96.79 set on December 11, 2019. They are under-performing the Nasdaq which is up 7.59% year to date.
Incyte follows other major Healthcare sector earnings this month
Incyte's report follows an earnings beat by J&J on January 22, who reported EPS of $1.88 on revenue of $20.75B, compared to forecasts EPS of $1.87 on revenue of $20.8B.
Novartis ADR had beat expectations on January 29 with fourth quarter EPS of $1.32 on revenue of $12.4B, compared to forecast for EPS of $1.31 on revenue of $12.33B.
Stay up-to-date on all of the upcoming earnings reports by visiting 's earnings calendar
